The brain has a remarkable capacity to undergo ongoing changes, which allow us to adapt to our environment. Brain plasticity depends on changes in specific subsets of genes, and one key mechanism that enables brain adaptation is epigenetic modification. These modifications involve physical changes to genes that regulate the activation or inhibition of specific genes through epigenetic modulators. One prominent example of such an epigenetic modulator is the gene MeCP2.
Previous studies have shown that MeCP2 is expressed at high levels in the brain and binds to specific regions across the genome. The importance of this gene in normal brain function has been highlighted through research on the rare and devastating neurodevelopmental disorder, Rett Syndrome. Patients with Rett syndrome are born without any prominent disabilities or neurological deficiencies during the early stages of development. However, between the ages of 1 and 2 years, the disease begins to manifest, leading to severe impairments in social, motor, sensory, and cognitive functions. Tragically, children with Rett syndrome experience a rapid deterioration in neurological abilities, which significantly shortens their lifespan.
Over 20 years ago, studies identified that Rett syndrome is genetically caused by mutations in the MeCP2 gene. A prominent question in neuroscience has been: How can mutations in a single gene lead to such devastating effects on brain development and function? Despite extensive research and a wealth of data on the role of MeCP2 in the brain, the precise function of MeCP2 in normal brain activity remains unclear. Understanding the normal function of MeCP2 is crucial for developing potential therapeutic strategies for Rett syndrome. Currently, despite numerous clinical efforts to develop gene therapies and drugs, Rett syndrome remains a progressive, devastating neurodevelopmental disorder, with no cure for patients.
